Biologics Spine BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease byTim AllenMay 7, 2026
Biologics Spine BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease byTim AllenFebruary 10, 2026
Biologics Regulatory Spine BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease byJosh SandbergNovember 17, 2025
Financial BioRestorative Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update byTim AllenAugust 12, 2025
Biologics Spine BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease byTim AllenJune 13, 2025
Financial BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update byTim AllenMay 14, 2025
Biologics Spine Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data byTim AllenMay 13, 2025
Biologics Spine BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data byTim AllenNovember 13, 2024
Biologics Regulatory BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health byTim AllenNovember 5, 2024
